ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/26/23	$0.000100	-0.99%	330
22/26/22	$0.000101	+1.00%	304
21/26/21	$0.000100	+9,900.00%	400
18/26/18	$0.000001	0.00%	1,763
17/26/17	$0.000001	-99.00%	3,170

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 01:09:06 24/09/2026 am IST			5-day change	1st Jan Change
0.000100 ^USD	-0.99%		0.00%	-

20/23/20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/23/20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	41.01L 36L 33.84L 30.94L 57.81L 39Cr 58.24L 4.06Cr 1.58Cr 20Cr 1.54Cr 1.51Cr 65Cr	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-12.96L -11.37L -10.69L -10L -18.26L -12Cr -18.4L -1.28Cr -49.78L -6.33Cr -48.66L -47.59L -21Cr	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/23/20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/23/20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
12/23/12	Insider Buy: Obseva	MT
06/23/06	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
01/23/01	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/23/31	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/23/22	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/23/15	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/23/13	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/23/13	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/23/13	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/23/13	ObsEva SA Announces Executive Changes	CI
03/23/03	Top Premarket Gainers	MT

30/22/30	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/22/01	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/22/29	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/22/03	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/22/26	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Share Price

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news: ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Price Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/23/20	ObsEva Announces Change of Central Securities Depositary	GL
20/23/20	ObsEva Announces Change of Central Securities Depositary	GL
01/23/01	ObsEva Files Year End 2022 Financial Statements	GL
23/23/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/23/15	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/23/20	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/23/06	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/23/06	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/23/01	Obseva bleibt 2022 tief in den roten Zahlen
01/23/01	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		0.4
5 years	0		3.27
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Ernest Loumaye	Buy	Chief Executive Officer	40,00,000	3.7138%
28/02/23	Ernest Loumaye	Buy	Chief Executive Officer	40,00,000	3.7138%
23/02/23	William Brown	Free	Chief Executive Officer	2,50,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	-0.99%	0.00%	0.00%	-99.83%	11.83T
WUXI APPTEC CO., LTD.	+0.06%	+6.49%	+60.29%	+111.13%	7.43TCr
ARGENX SE	-2.29%	-1.51%	+33.30%	+75.07%	6.12TCr
INSMED INCORPORATED	-2.05%	-3.46%	-18.60%	+352.20%	2.64TCr
BIONTECH SE	-2.39%	+2.74%	+0.19%	-5.91%	2.53TCr
GENMAB A/S	+0.57%	+3.66%	+25.59%	-9.37%	2.08TCr
PHARMAESSENTIA CORPORATION	+1.29%	-2.49%	+152.11%	+333.06%	1.52TCr
EXELIXIS, INC.	-2.44%	-0.09%	+42.50%	+164.11%	1.44TCr
SUMMIT THERAPEUTICS INC.	-3.91%	-4.91%	-14.10%	+779.68%	1.37TCr
MADRIGAL PHARMACEUTICALS, INC.	-1.12%	-3.04%	+15.72%	+234.56%	1.2TCr
Average	-1.33%	+0.03%	+29.70%	+193.47%	2.63TCr
Weighted average by Cap.	-1.22%	+1.01%	+36.01%	+162.09%

	2021	2022
Net sales	-	1.96Cr 1.72Cr 1.62Cr 1.48Cr 2.77Cr 188.11Cr 2.79Cr 19Cr 7.54Cr 96Cr 7.37Cr 7.21Cr 310.94Cr
Net income	-5.84Cr -5.12Cr -4.82Cr -4.4Cr -8.23Cr -559.2Cr -8.29Cr -58Cr -22Cr -285.1Cr -22Cr -21Cr -924.37Cr	-2.99Cr -2.62Cr -2.47Cr -2.25Cr -4.21Cr -286.22Cr -4.24Cr -30Cr -11Cr -145.92Cr -11Cr -11Cr -473.12Cr
Net Debt	-2.81Cr -2.46Cr -2.32Cr -2.12Cr -3.96Cr -268.93Cr -3.99Cr -28Cr -11Cr -137.11Cr -11Cr -10Cr -444.55Cr	-53.97L -47.37L -44.53L -40.71L -76.07L -52Cr -76.64L -5.35Cr -2.07Cr -26Cr -2.03Cr -1.98Cr -85Cr